| Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016 | 9664 | 2016 |
| Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018 | 5831 | 2018 |
| Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater M Reck, D Rodríguez–Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 37 (7), 537-546, 2019 | 1438 | 2019 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1286 | 2018 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1069 | 2019 |
| Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ... Journal of clinical oncology 38 (14), 1505-1517, 2020 | 945 | 2020 |
| Volatile organic compounds of lung cancer and possible biochemical pathways M Hakim, YY Broza, O Barash, N Peled, M Phillips, A Amann, H Haick Chemical reviews 112 (11), 5949-5966, 2012 | 888 | 2012 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 706 | 2020 |
| Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50% M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 39 (21), 2339-2349, 2021 | 680 | 2021 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 637 | 2018 |
| Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules MK Nakhleh, H Amal, R Jeries, YY Broza, M Aboud, A Gharra, H Ivgi, ... ACS nano 11 (1), 112-125, 2017 | 504 | 2017 |
| Biomarkers in lung cancer screening: achievements, promises, and challenges LM Seijo, N Peled, D Ajona, M Boeri, JK Field, G Sozzi, R Pio, JJ Zulueta, ... Journal of Thoracic Oncology 14 (3), 343-357, 2019 | 429 | 2019 |
| Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ... Journal of Thoracic Oncology 11 (9), 1493-1502, 2016 | 390 | 2016 |
| Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021 | 383 | 2021 |
| Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403-1410, 2017 | 351 | 2017 |
| Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ... Annals of Oncology 32 (7), 881-895, 2021 | 349 | 2021 |
| Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open … JR Brahmer, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... The Lancet Oncology 18 (12), 1600-1609, 2017 | 349 | 2017 |
| Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment N Peled, EG Abinader, G Pillar, D Sharif, P Lavie Journal of the American College of Cardiology 34 (6), 1744-1749, 1999 | 340 | 1999 |
| Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors E Izumchenko, K Paz, D Ciznadija, I Sloma, A Katz, D Vasquez-Dunddel, ... Annals of Oncology 28 (10), 2595-2605, 2017 | 292 | 2017 |
| ESR/ERS white paper on lung cancer screening HU Kauczor, L Bonomo, M Gaga, K Nackaerts, N Peled, M Prokop, ... European radiology 25, 2519-2531, 2015 | 287 | 2015 |
Giora PillarProfessor of sleep research and pediatrics在 technion.ac.il 的电子邮件经过验证
